Dupilumab side effect in a patient with atopic dermatitis: a case report study

被引：32

作者：

Albader, Sakhar S. ^{[1
]}

Alharbi, Abdulmajeed A. ^{[2
]}

Alenezi, Rakan F. ^{[1
]}

Alsaif, Fahad M. ^{[3
]}

机构：

[1] King Saud Univ, Coll Med, P Box 145111, Riyadh 4545, Saudi Arabia

[2] Alqassim Univ, Coll Med, Qasim, Saudi Arabia

[3] King Saud Univ, Coll Med, Div Dermatol, Riyadh, Saudi Arabia

来源：

BIOLOGICS-TARGETS & THERAPY | 2019年 / 13卷

关键词：

atopic dermatitis; dupilumab; eczema; adverse effect; PLACEBO;

D O I：

10.2147/BTT.S195512

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.

引用

页码：79 / 82

页数：4

共 14 条

[1] Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial [J].

Bachert, Claus ;

Mannent, Leda ;

Naclerio, Robert M. ;

Mullol, Joaquim ;

Ferguson, Berrylin J. ;

Gevaert, Philippe ;

Hellings, Peter ;

Jiao, Lixia ;

Wang, Lin ;

Evans, Robert R. ;

Pirozzi, Gianluca ;

Graham, Neil M. ;

Swanson, Brian ;

Hamilton, Jennifer D. ;

Radin, Allen ;

Gandhi, Namita A. ;

Stahl, Neil ;

Yancopoulos, George D. ;

Sutherland, E. Rand .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (05) :469-479

[2]

Barnes Alexander C, 2017, Am J Ophthalmol Case Rep, V7, P120, DOI 10.1016/j.ajoc.2017.06.017

[3] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].

Blauvelt, Andrew ;

de Bruin-Weller, Marjolein ;

Gooderham, Melinda ;

Cather, Jennifer C. ;

Weisman, Jamie ;

Pariser, David ;

Simpson, Eric L. ;

Papp, Kim A. ;

Hong, H. Chih-Ho ;

Rubel, Diana ;

Foley, Peter ;

Prens, Errol ;

Griffiths, Christopher E. M. ;

Etoh, Takafumi ;

Pinto, Pedro Herranz ;

Pujol, Ramon M. ;

Szepietowski, Jacek C. ;

Ettler, Karel ;

Kemeny, Lajos ;

Zhu, Xiaoping ;

Akinlade, Bolanle ;

Hultsch, Thomas ;

Mastey, Vera ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Amin, Nikhil ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Stahl, Neil ;

Yancopoulos, George D. ;

Shumel, Brad .

LANCET, 2017, 389 (10086) :2287-2303

[4]

Dalia Y, 2018, PRACT DERMATOL, V4, DOI [10.1016/j.jaad.2005.02.014, DOI 10.1016/J.JAAD.2005.02.014]

[5] Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis [J].

Eshtiaghi, Panteha ;

Gooderham, Melinda J. .

CORE EVIDENCE, 2018, 13 :13-20

[6] Failure of omalizumab for treatment of severe adult atopic dermatitis [J].

Krathen, RA ;

Hsu, S .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (02) :338-340

[7] Treatment of recalcitrant atopic dermatitis with omalizumab [J].

Lane, JE ;

Cheyney, JM ;

Lane, TN ;

Kent, DE ;

Cohen, DJ .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (01) :68-72

[8] A Comprehensive Review of the Treatment of Atopic Eczema [J].

Lee, Ji Hyun ;

Son, Sag Wook ;

Cho, Sang Hyun .

ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2016, 8 (03) :181-190

[9]

Mitchell Krystal, 2018, JAAD Case Rep, V4, P143, DOI 10.1016/j.jdcr.2017.11.020

[10] Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis [J].

Ou, Zuzhen ;

Chen, Chao ;

Chen, Aijun ;

Yang, Yao ;

Zhou, Weikang .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 :303-310

← 1 2 →